The market, valued at USD 8 billion in 2025, is set to evolve as pharmaceutical developers shift toward highly targeted therapies. Analysts point to a robust pipeline of next-generation treatments, including anti-B7-H3 antibody-drug conjugates, PROTAC protein degraders, and novel radionuclide therapies, as the primary engines for this growth. The United States currently leads this landscape, holding the largest market share among the regions studied.

Key players such as Pfizer, Curium, and Telix Pharmaceuticals are advancing clinical candidates like mevrometostat and various PSMA-targeted radioligands to address unmet needs in both first- and second-line settings. The integration of PSMA-PET imaging and biomarker-driven selection is already reshaping clinical practice, moving the industry away from broad-spectrum treatments toward more personalized, effective interventions. As these therapies transition from clinical trials to regulatory approval, they are expected to displace or supplement established blockbusters like Pluvicto, creating a new standard of care for patients with advanced disease.